SFA Therapeutics

11:15 AM - 11:30 AM, Tuesday, June 4, 2019 ・ Theater 4
SFA Therapeutics is a development-stage bio-pharmaceutical startup company focused on a new advancement in the treatment inflammatory diseases, targeting NF-Kb. Chronic inflammation has been implicated in a wide range of diseases, including rheumatoid arthritis, psoriatic arthritis, lupus (SLE), inflammatory bowel disease (IBD), Crohn's Disease, Psoriasis, Liver Disease and even certain forms of cancer. Our small-molecule drugs are derived from natural substances identified at Temple University and enable a new platform for developing treatments potentially aimed at over 65 inflammatory diseases currently afflicting patients; with safer treatments than current therapies. Our initial focus is in Psoriasis and Liver Disease (Hepatitis B, NASH and HCC). Patents have been filed in both diseases, based on animal data in Liver Disease and on a small human trial in Psoriasis.
Ticker:
Not Provided.
Exchange:
Not Provided.
Company Type:
Company Website:
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
SFA002 for Psoriasis
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5
Speaker
photo
CEO
SFA Therapeutics